RAPT Therapeutics, Inc.RAPTEarnings & Financial Report
Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.
RAPT Q3 2023 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-33.9M
Net Profit
$-31.4M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.82
RAPT Therapeutics, Inc. Q3 2023 Financial Summary
RAPT Therapeutics, Inc. reported revenue of $0 for Q3 2023, with a net profit of $-31.4M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-31.4M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 2023 |
RAPT Therapeutics, Inc. Annual Revenue by Year
RAPT Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $1.5M).
| Year | Annual Revenue |
|---|---|
| 2022 | $1.5M |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Revenue | $641000 | $886000 | $0 | $0 | $0 | $0 |
| YoY Growth | -47.5% | 2.0% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Assets | $187.5M | $222.0M | $209.5M | $266.2M | $220.8M | $199.7M |
| Liabilities | $19.7M | $19.9M | $20.2M | $21.0M | $21.1M | $26.9M |
| Equity | $167.8M | $202.1M | $189.3M | $245.2M | $199.7M | $172.8M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Operating CF | $-15.6M | $-15.2M | $-17.1M | $-22.8M | $-28.8M | $-21.9M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M